- Policy
- Finding ways to utilize the Patent-approval linkage system
- by Lee, Hye-Kyung Mar 10, 2022 05:53am
- The MFDS plans to prepare a collection of data so that domestic pharmaceutical companies can pioneer the Chinese pharmaceutical market by utilizing the Patent-approval linkage system within the first half of this year. The MFDS recently announced research services for "Overseas the Patent-approval Linkage System Survey and Domestic Impact Ana
- Company
- Keytruda for esophageal cancer indications is imminent
- by Eo, Yun-Ho Mar 8, 2022 06:08am
- Keytruda, an immuno-cancer drug, is expected to be able to be prescribed for esophageal cancer. According to related industries, the MFDS has finally reviewed the first round of local progressive or metastatic esophageal cancer (GEJ), in which PD-1 inhibitory immuno-cancer drug Keytruda (Pembrolizumab) of MSD is non-resectable. Permission is
- Company
- Generation shift of ALK targeted drugs... rise of Alecensa
- by Mar 8, 2022 06:08am
- The targeted cancer therapy market for patients with ALK mutations has been restructured around second-generation drugs. The share of the first-generation drug Xalkori, which used to occupy 2/3 of the market fell to 20%, and the representative second-generation drug ‘Alecensa' took over the market. However, Alunbrig, a latecomer into the second
- Company
- Domestic production of Sputnik V was delayed
- by Kim, Jin-Gu Mar 8, 2022 06:08am
- Due to the war between Russia and Ukraine, shipments of domestic companies that consignment produce the COVID-19 vaccine Koruspharm developed by Russia are also being postponed indefinitely. Koruspharm said in a telephone interview with Dailypharm on the 4th, "We are continuously talking to the Russian side via e-mail or phone call even af
- Policy
- The fatality rate of Omicron is low
- by Lee, Jeong-Hwan Mar 8, 2022 06:08am
- The quarantine authorities announced a full-fledged easing of distancing, saying that it is becoming clearer that the COVID-19 Omicron mutation has a lower severity and fatality rate than the delta mutation. From the 5th to the 20th, the 22 o'clock operating hours limit, which will be applied to groups 1, 2, and 3, will be increased by 1 hour
- Policy
- DREC rejects reimb of neurofibromatosis drug ‘Koselugo'
- by Lee, Tak-Sun Mar 8, 2022 06:08am
- The new neurofibromatosis drug ‘Koselugo (selumetinib),’ failed to receive reimbursement benefits in Korea. The Health Insurance Review and Assessment Service decided the drug as a ‘non-benefit' after deliberation on the adequacy of providing medical benefit for the drug at the 3rd Drug Reimbursement Evaluation Committee that was held thi
- Company
- Changes in the lung cancer treatment market are detected
- by Mar 7, 2022 05:50am
- Changes are detected in the EGFR targeted anticancer drug market, which Tagrisso dominated. Tagrisso sales stagnated for the first time due to sluggish primary treatment benefits. Leclaza, the only domestic new drug in the market, is threatening Tagrisso. According to IQVIA, a pharmaceutical research institute, on the 5th, the size of the dom
- Opinion
- [Reporter’s View] Keytruda’s ‘trade-off’ reimbursement
- by Eo, Yun-Ho Mar 7, 2022 05:49am
- At last, Keytruda was finally approved to extend its reimbursement to first-line in lung cancer. However, whispers are rising on its approval, which was made four long years after the company applied for its reimbursement. The keyword is ’trade-off.’ Trade-offs, which refer to the policy direction in which pharmaceutical companies who
- Company
- Immuno-oncology drugs make ₩400 billion after 7 years
- by Mar 7, 2022 05:49am
- The immuno-oncology drug market exceeded &8361;400 billion in annual sales only 7 years since its debut in Korea. With Keytruda in the lead making over &8361;200 billion in sales, the latecomers Tecentriq and Imfinzi are chasing the lead with its rapid growth. According to the market research institution IQVIA on the 4th, the total imm
- Company
- Organon is focusing on expanding the women's health lineup
- by Mar 7, 2022 05:49am
- The demand for unmet diseases related to women's entire life cycle was relatively high. Organon will focus on improving treatment accessibility so that all women can enjoy healthier daily lives." At a press conference held by Organon for the first time since its launch at The Plaza Hotel in Jung-gu, Seoul on the morning of the 2nd, CEO Kim So-e
